- Home
- MTRX vs GHRS Comparison
MTRX vs GHRS Comparison
Compare MTRX & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTRX
- GHRS
- Stock Information
- Founded
- MTRX 1984
- GHRS 2018
- Country
- MTRX United States
- GHRS Ireland
- Employees
- MTRX N/A
- GHRS N/A
- Industry
- MTRX Engineering & Construction
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- MTRX Consumer Discretionary
- GHRS Health Care
- Exchange
- MTRX Nasdaq
- GHRS Nasdaq
- Market Cap
- MTRX 366.9M
- GHRS 402.7M
- IPO Year
- MTRX 1990
- GHRS 2021
- Fundamental
- Price
- MTRX $13.16
- GHRS $8.25
- Analyst Decision
- MTRX Strong Buy
- GHRS Strong Buy
- Analyst Count
- MTRX 1
- GHRS 3
- Target Price
- MTRX $18.00
- GHRS $35.67
- AVG Volume (30 Days)
- MTRX 113.4K
- GHRS 55.0K
- Earning Date
- MTRX 02-05-2025
- GHRS 11-14-2024
- Dividend Yield
- MTRX N/A
- GHRS N/A
- EPS Growth
- MTRX N/A
- GHRS N/A
- EPS
- MTRX N/A
- GHRS N/A
- Revenue
- MTRX $696,133,000.00
- GHRS N/A
- Revenue This Year
- MTRX $28.10
- GHRS N/A
- Revenue Next Year
- MTRX $13.85
- GHRS N/A
- P/E Ratio
- MTRX N/A
- GHRS N/A
- Revenue Growth
- MTRX N/A
- GHRS N/A
- 52 Week Low
- MTRX $8.61
- GHRS $5.08
- 52 Week High
- MTRX $13.90
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- MTRX 54.29
- GHRS 45.97
- Support Level
- MTRX $12.72
- GHRS $7.29
- Resistance Level
- MTRX $13.39
- GHRS $8.91
- Average True Range (ATR)
- MTRX 0.39
- GHRS 0.79
- MACD
- MTRX -0.06
- GHRS -0.08
- Stochastic Oscillator
- MTRX 58.33
- GHRS 31.55
About MTRX Matrix Service Company
Matrix Service Co is an engineering and construction provider for large industrial projects, primarily in the oil and gas, power, petrochemical, industrial, mining, and minerals markets. It offers engineering, fabrication, construction, and maintenance services, operating across three segments namely Utility and Power Infrastructure; Process and Industrial Facilities; and Storage and Terminal Solutions.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.